20:10 , Mar 1, 2019 |  BC Week In Review  |  Company News

Clovis gains on 4Q increase in Rubraca sales

Clovis Oncology Inc. (NASDAQ:CLVS) reported $30.4 million in 4Q18 revenue, all from U.S. sales of Rubraca rucaparib, up 78% from $17 million in 4Q17 and beating the consensus estimate of $27 million. For the year,...
20:43 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Dec. 14, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The...
17:51 , Dec 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson's disease (PD) Cell culture and mouse studies suggest PARP inhibitors could help treat PD. In primary mouse cortical neurons cultured with α-synuclein fibrils, the PARP inhibitors veliparib, Rubraca rucaparib and Talzenna talazoparib decreased...
23:22 , Dec 14, 2018 |  BC Extra  |  Company News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Friday, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The agency...
20:53 , Dec 7, 2018 |  BC Week In Review  |  Company News

European patent for Clovis' Rubraca upheld

The European Patent Office upheld a patent covering the crystalline formulation of Rubraca rucaparib from Clovis Oncology Inc. (NASDAQ:CLVS), confirming patent protection through 2031. The company has filed for a supplementary protection certificate that would...
00:12 , Nov 7, 2018 |  BC Extra  |  Preclinical News

Hopkins study props up PARP inhibitors for Parkinson's

A study in mice showed the potential of repurposed PARP-1 inhibitors to reverse aggregate α-synuclein-induced neuronal cell death in Parkinson's disease. PARP inhibitors Lynparza olaparib, Zejula niraparib, Talzenna talazoparib and Rubraca rucaparib are marketed or...
22:16 , Oct 31, 2018 |  BC Extra  |  Company News

Clovis falls on lower-than-expected Rubraca sales, guidance

Clovis Oncology Inc. (NASDAQ:CLVS) lost $4.98 (30%) to $11.63 on Wednesday after reporting that ovarian cancer drug Rubraca rucaparib generated 3Q18 sales of $22.8 million, less than analyst estimates of $30.3 million. Although the figure...
21:20 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Clovis' Rubraca leads to 44% ORR in Phase II for CRPC

Clovis Oncology Inc. (NASDAQ:CLVS) said twice-daily oral Rubraca rucaparib led to a confirmed objective response rate (ORR) by investigator assessment of 44% in 25 evaluable patients with a BRCA1/2 mutation in the Phase II TRITON2...
19:08 , Aug 3, 2018 |  BC Week In Review  |  Financial News

Impact raises $30M series C

Impact Therapeutics Inc. (Nanjing, China) raised $30 million in an untranched series C round led by new investor Decheng Capital. Existing investor Lilly Asia Ventures also participated. Impact is developing IMP4297, a PARP-1 inhibitor that...
19:50 , Aug 2, 2018 |  BC Extra  |  Financial News

Impact raises $30M series C

Impact Therapeutics Inc. (Nanjing, China) raised $30 million in an untranched series C round led by new investor Decheng Capital. Existing investor Lilly Asia Ventures also participated. Impact is developing IMP4297, a PARP-1 inhibitor that...